Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | ASAH2 | Q9NR71 | 2/20 | 0.71 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.70 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133213 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL13863420 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973496 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL5527047 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22911186 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973426 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL24032894 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973497 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22910831 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22910800 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094669-A | Nucleic acid delivery compositions | — | 2026-05-26 | — | — | CN | claimed |
| US-20260086103-A1 | BIOMARKERS FOR CARDIOVASCULAR EVENTS | ZORA BIOSCIENCES OY (FI) | 2026-03-26 | — | — | US | claimed |
| EP-4680721-A1 | BIOPRODUCTION OF GANGLIOSIDES IN RECOMBINANT HOST CELLS | Recombia Biosciences, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-20250355006-A1 | BIOMARKERS FOR CARDIOVASCULAR EVENTS | ZORA BIOSCIENCES OY (FI) | 2025-11-20 | — | — | US | claimed |
| US-12399188-B2 | Biomarkers for cardiovascular events | ZORA BIOSCIENCES OY (FI) | 2025-08-26 | — | — | US | claimed |
| US-20250264481-A1 | METHODS FOR PREDICTION AND EARLY DETECTION OF DIABETES | Baker Heart and Diabetes Institute (AU) | 2025-08-21 | — | — | US | claimed |
| EP-4584595-A1 | METHODS OF IDENTIFYING PANCREATIC CANCER | Prognomiq, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| CN-120064491-A | Markers for ALS, kits, methods, systems and uses | 首都医科大学附属北京儿童医院 | 2025-05-30 | — | — | CN | claimed |
| CN-119816897-A | Multiple study assessment | 普罗科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-12270816-B2 | Lipidomic biomarkers for identification of high-risk coronary artery disease patients | ZORA BIOSCIENCES OY (FI) | 2025-04-08 | — | — | US | claimed |
| WO-2023108294-A1 | DIAGNOSTIC LIPID BIOMARKERS FOR COVID-19 AND METHODS FOR USE THEREOF | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-06-22 | — | — | WO | claimed |
| US-11529370-B2 | Use of composition comprising stem cell-derived exosome as effective ingredient in strengthening skin barrier and improving skin barrier function | EXOCOBIO INC. (KR) | 2022-12-20 | — | — | US | claimed |
| US-20220362177-A1 | CERAMIDE RATIOS AS PREDICTIVE AND THERAPEUTIC BIOMARKERS FOR LEUKEMIAS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-11-17 | — | — | US | claimed |
| EP-4089416-A1 | CERAMIDES AND THEIR USE IN DIAGNOSING CARDIOVASCULAR DISEASES | Zora Biosciences OY (FI) | 2022-11-16 | — | — | EP | claimed |
| US-11474116-B2 | Ceramides and their use in diagnosing CVD | ZORA BIOSCIENCES, OY (FI) | 2022-10-18 | — | — | US | claimed |
| US-20220170066-A1 | DIFFERENTIATION OF LYME DISEASE AND SOUTHERN TICK-ASSOCIATED RASH ILLNESS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2022-06-02 | — | — | US | claimed |
| US-20220163547-A1 | CERAMIDES AND THEIR USE IN DIAGNOSING CVD | ZORA BIOSCIENCES OY (FI) | 2022-05-26 | — | — | US | claimed |
| WO-2022081567-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | BRIGHTSEED, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114354775-A | Method for constructing and applying acute coronary syndrome diagnosis model | 江苏品生医疗科技集团有限公司 | 2022-04-15 | — | — | CN | claimed |
| WO-2022075627-A1 | COMPOSITION FOR DIAGNOSIS OR PREDICTION OF METABOLIC SYNDROME OR GROUP AT HIGH RISK OF EXPRESSION OF BLOOD CERAMIDE | 주식회사 에스씨엘헬스케어 | 2022-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220163547-A1 | CERAMIDES AND THEIR USE IN DIAGNOSING CVD | CERS2, SGMS1, CERT1 | CETP 17/4885THRB 4584/4885MEN1 2409/4885 |
| US-11474116-B2 | Ceramides and their use in diagnosing CVD | CERS2, SGMS1, CERT1 | CETP 17/4885THRB 4584/4885MEN1 2409/4885 |
| US-20260086103-A1 | BIOMARKERS FOR CARDIOVASCULAR EVENTS | SGMS1, CERS2, SGMS2 | CETP 12/4885THRB 3122/4885MEN1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.